Search
Cefdinir
go.drugbank.com/drugs/DB00535ApprovedInvestigationalCefdinir, also known as Omnicef, is a semi-synthetic, broad-spectrum antibiotic belonging to the third generation of the cephalosporin class.
Poliglusam
go.drugbank.com/drugs/DB11234ApprovedInvestigationalAs a rich source of dietary fiber, chitosan is used as a food ingredient or additive. … In comparison, commercial poliglusam is derived from deacetylation of chitin contained in the shells of various sea crustaceans such as shrimps [L999].
Loncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigational[A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.
Hydroflumethiazide
go.drugbank.com/drugs/DB00774ApprovedWithdrawnA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnIt is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form . … The same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis.
Nabumetone
go.drugbank.com/drugs/DB00461ApprovedNabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID). … [label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen].
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalIt is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies.
Digoxin Immune Fab (Ovine)
go.drugbank.com/drugs/DB00076ApprovedIt is used as an antidote for overdose of digoxin.
Antazoline
go.drugbank.com/drugs/DB08799ApprovedIt is also formulated as eye drops with naphazoline to relieve allergic conjunctivitis.
Sunvozertinib
go.drugbank.com/drugs/DB18925Investigational[A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor